1 2 aim

VISION-DMD End Event: Vamorolone Clinical Trial Results

After four years of intense work, the VISION-DMD consortium will share the findings and output from the VISION-DMD project, and the investigation of Vamorolone. Registrations for the online event on Wednesday December 1 are now open. This event will be a satellite event of the Duchenne Patient Academy

This collaborative global project was aiming to develop a safe, effective and affordable therapy for Duchenne Muscular Dystrophy (DMD). This was being done by investigating the safety and efficacy of Vamolorone (VBP15) in ambulant DMD boys.

On Wednesday December 1st, 15:00 – 16:00 CET, you are invited to join families, researchers, patient organisations and clinicians to the online end event and discussion of this project.


Next to a presentation on the project’s approach and results, the Principle Investigator will present the outcomes of the clinical trial. These presentations will be followed by an interactive discussion where the speakers will answer questions from the audience.


15:00 – 15:05      Welcome & Introduction, Dr. Michela Guglieri
15:05 – 15:15      About VISION-DMD, Dr. Eric Hoffman
15:15 – 15:35      Clinical Trial results, Dr. Michela Guglieri
15:35 – 15:45      Next Steps, Dr. Eric Hoffman
15:45 – 16:00      Questions and Answers, moderator Suzie-Ann Bakker

About Vamorolone

Vamorolone is an innovative steroid-like drug designed to retain or improve corticosteroid efficacy and increase membrane stabilization with the potential for reduced side effects. Preclinical studies suggest that vamorolone has the potential to increase the therapeutic window, slow disease progression, and improve quality of life and lifespan for all DMD patients. VISION-DMD is an advanced and innovative clinical program to develop a safe, effective and affordable therapy for DMD.